Asia-Pacific Glaucoma Treatment Companies

Top Industry Leaders in the Asia Pacific Glaucoma Treatment Market

Asia-Pacific Glaucoma Treatment Key Companies

Latest Asia-Pacific Glaucoma Treatment Companies Update

Santen Pharmaceutical Co., Ltd. announces regulatory approval for its Rhokinase inhibitor, Roclatan®, in mainland China, expanding its reach in the largest Glaucoma market in the Asia-Pacific region.

Senju Pharmaceutical Co., Ltd. receives marketing authorization for its prostaglandin analog Travatan® in Indonesia, offering another treatment option for patients in the region.Aeon Vis launches its glaucoma drainage implant, Aquaflow®, in South Korea, providing a minimally invasive alternative for managing severe glaucoma cases.

Glaukos Corporation partners with Alcon Laboratories to distribute its iStent® Inject Trabecular Micro-Bypass System in India and South Korea, leveraging Alcon's established distribution network to reach more patients.

Merck & Co., Inc. collaborates with Bausch + Lomb to develop and commercialize novel therapies for glaucoma in the Asia-Pacific region, combining their expertise and resources to accelerate drug development and market access.

List of Asia-Pacific Glaucoma Treatment Key Companies in the Market

Novartis AG

Pfizer Inc.

Allergan

Merck & Co.

Ocular Therapeutix Inc

pSivida Corp

Icon Bioscience Inc

Amorphex Therapeutics LLC.

Ellex

Quantel

Lumenis

and Lightmed

Asia Pacific Glaucoma Treatment Companies

Glaucoma is a group of eye conditions that can cause optic nerve damage and vision loss. The treatment landscape includes medications, surgical procedures, and medical devices aimed at managing intraocular pressure and preserving vision.

Top Industry Leaders in the Asia Pacific Glaucoma Treatment Market